NCT00171769
Completed
Phase 3
An Open Label, Multi-center Trial to Evaluate the Feasibility and Safety of Short-term Treatment With Subcutaneously Injected Certoparin (8000 U Anti-Xa Twice Daily) in Patients With Persistent Nonvalvular Atrial Fibrillation
DrugsCertoparin
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Persistent Nonvalvular Atrial Fibrillation
- Sponsor
- Novartis
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Safety measures including reporting of serious adverse events and adverse events, including vascular and neurological events
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation
Investigators
Eligibility Criteria
Inclusion Criteria
- •persistent AF (electrical cardioversion is planned)
- •written informed consent
Exclusion Criteria
- •acute clinical signs of venous thromboembolism
- •current oral anticoagulation
- •indication for medical cardioversion
Outcomes
Primary Outcomes
Safety measures including reporting of serious adverse events and adverse events, including vascular and neurological events
Study Sites (1)
Loading locations...
Similar Trials
Terminated
N/A
Multicenter Study of the Avenue L Interbody Spinal Fusion System Using VerteBRIDGE Plating and Posterior FixationDegenerative Disc DiseaseNCT02068768LDR Spine USA13
Completed
N/A
Clinical Effectiveness of DermACELL AWM in Subjects With Chronic Venous Leg UlcersVenous Leg UlcerNCT03589586LifeNet Health100
Recruiting
Phase 2
The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular HemorrhageCommunicating HydrocephalusCerebral Intraventricular HemorrhageSecondary Normal Pressure HydrocephalusPost Hemorrhagic HydrocephalusNCT06563817Beijing Tiantan Hospital53
Recruiting
Phase 2
Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMMMultiple Myeloma in RelapseNCT06255847Shanxi Bethune Hospital43
Completed
Phase 2
Study for Patients Who Have Benefited and Tolerated Prior Panitumumab TreatmentColorectal CancerNon-Small Cell Lung CancerProstate CancerSolid TumorsAdvanced Renal Cell CarcinomaNCT00425204Amgen31